DK0482089T3 - Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker - Google Patents

Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker

Info

Publication number
DK0482089T3
DK0482089T3 DK90911718.6T DK90911718T DK0482089T3 DK 0482089 T3 DK0482089 T3 DK 0482089T3 DK 90911718 T DK90911718 T DK 90911718T DK 0482089 T3 DK0482089 T3 DK 0482089T3
Authority
DK
Denmark
Prior art keywords
treatment
uveoretinitis
autoimmune
uveoretnitis
humans
Prior art date
Application number
DK90911718.6T
Other languages
Danish (da)
English (en)
Inventor
Howard L Weiner
David A Hafler
Robert B Nussenblatt
Alan G Palestine
Original Assignee
Autoimmune Inc
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Autoimmune Inc, Us Health filed Critical Autoimmune Inc
Application granted granted Critical
Publication of DK0482089T3 publication Critical patent/DK0482089T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Rheumatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Emergency Protection Circuit Devices (AREA)
DK90911718.6T 1989-07-14 1990-07-16 Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker DK0482089T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37977889A 1989-07-14 1989-07-14
US55163290A 1990-07-10 1990-07-10

Publications (1)

Publication Number Publication Date
DK0482089T3 true DK0482089T3 (da) 1998-05-25

Family

ID=27008768

Family Applications (1)

Application Number Title Priority Date Filing Date
DK90911718.6T DK0482089T3 (da) 1989-07-14 1990-07-16 Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker

Country Status (15)

Country Link
US (1) US5961977A (ja)
EP (1) EP0482089B1 (ja)
JP (1) JP2607751B2 (ja)
KR (1) KR0159046B1 (ja)
AT (1) ATE158950T1 (ja)
AU (1) AU670024B2 (ja)
BR (1) BR9007527A (ja)
CA (1) CA2063416C (ja)
DE (1) DE69031563T2 (ja)
DK (1) DK0482089T3 (ja)
ES (1) ES2109234T3 (ja)
FI (1) FI920139A0 (ja)
HU (1) HUT63182A (ja)
NO (1) NO920127D0 (ja)
WO (1) WO1991001333A1 (ja)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE158950T1 (de) * 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
IL99699A (en) 1990-10-10 2002-04-21 Autoimmune Inc Drug with the option of oral, intra-intestinal, or inhaled dosing for suppression of autoimmune response associated with type I diabetes
US5891435A (en) * 1993-04-16 1999-04-06 Research Corporation Technologies, Inc. Methods and compositions for delaying or preventing the onset of autoimmune disease
WO1996039176A1 (en) * 1995-06-05 1996-12-12 Brigham & Women's Hospital USE OF ORAL TOLERANCE TO SUPPRESS BOTH Th1 AND Th2 IMMUNE RESPONSES AND TO SUPPRESS ANTIBODY PRODUCTION
US20050197283A1 (en) * 1998-10-04 2005-09-08 Vascular Biogenics Ltd. Compositions containing beta 2-glycoprotein I for the prevention and/or treatment of vascular disease
IL126447A (en) * 1998-10-04 2004-09-27 Vascular Biogenics Ltd An immune preparation that confers tolerance in oral administration and its use in the prevention and / or treatment of atherosclerosis
US7534605B2 (en) * 1999-06-08 2009-05-19 Yissum Research Development Company Of The Hebrew University Of Jerusalem CD44 polypeptides, polynucleotides encoding same, antibodies directed thereagainst and method of using same for diagnosing and treating inflammatory diseases
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ATE367823T1 (de) 2000-05-24 2007-08-15 Us Health E-selectin zur behandlung oder vorbeugung von schlaganfall
IL164202A0 (en) * 2002-03-26 2005-12-18 Yeda Res & Dev Use of an organ-specific pathogenic self-antigen for treatment of a non-autoimmune disease of said organ
EP1551495A4 (en) 2002-10-10 2010-06-02 Yeda Res & Dev BASIC ESTERS OF FAT ALCOHOLS AND THEIR USE AS ANTI-INFLAMMATORY OR IMMUNOMATORY AGENTS
US20090068207A1 (en) * 2005-04-15 2009-03-12 Vascular Biogenics Ltd. Compositions Containing Beta 2-Glycoprotein I-Derived Peptides for the Prevention and/or Treatment of Vascular Disease
US8968731B2 (en) * 2009-10-09 2015-03-03 Csl Limited Treatment of uveitis
JP6671363B2 (ja) 2014-07-15 2020-03-25 イッサム リサーチ ディヴェロップメント カンパニー オブ ザ ヘブリュー ユニバーシティー オブ エルサレム リミティッド Ｃｄ４４の単離されたポリペプチドおよびその使用
EP3557958B1 (en) 2016-12-19 2023-07-12 Panasonic Intellectual Property Management Co., Ltd. Attachment device, electronic device, attachment device securing method, and sheet

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1336954C (en) * 1987-06-24 1995-09-12 Howard L. Weiner Treatment of autoimmune diseases by oral administration of autoantigens
ATE158950T1 (de) * 1989-07-14 1997-10-15 Autoimmune Inc Behandlung der autoimmunen uveoretinitis in menschen
DE69033487T2 (de) * 1989-12-20 2000-06-29 Autoimmune, Inc. Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol

Also Published As

Publication number Publication date
BR9007527A (pt) 1992-06-23
CA2063416C (en) 2000-05-30
US5961977A (en) 1999-10-05
HUT63182A (en) 1993-07-28
HU9200107D0 (en) 1992-04-28
JPH05501866A (ja) 1993-04-08
KR0159046B1 (ko) 1998-11-16
FI920139A0 (fi) 1992-01-13
DE69031563D1 (de) 1997-11-13
EP0482089B1 (en) 1997-10-08
ES2109234T3 (es) 1998-01-16
DE69031563T2 (de) 1998-02-12
WO1991001333A1 (en) 1991-02-07
NO920127L (no) 1992-01-09
AU670024B2 (en) 1996-07-04
EP0482089A4 (en) 1993-02-17
CA2063416A1 (en) 1991-01-15
ATE158950T1 (de) 1997-10-15
AU6058390A (en) 1991-02-22
JP2607751B2 (ja) 1997-05-07
EP0482089A1 (en) 1992-04-29
NO920127D0 (no) 1992-01-09

Similar Documents

Publication Publication Date Title
DE69033487D1 (de) Behandlung von autoimmunkrankheiten durch verabreichung von autoantigenen in form von aerosol
DK0482089T3 (da) Fremgangsmåder til behandling af autoimmun uveoretnitis i mennesker
DE69133516D1 (de) Behandlung von autoimmunkrankheiten durch orale verabreichung von autoantigenen
ATE204178T1 (de) Methode zur behandlung und vorbeugung von typ-1 diabetis durch orale verabreichung von insulin
ATE157257T1 (de) Verstärkung der unterdrückungsregulation von autoimmunkrankheiten durch orale oder enterale verabreichung von autoantigenen
ATE140388T1 (de) Zusammensetzungen enthaltend omega conotoxin peptide derivate und deren verwendung zur behandlung von ischämie-artigen neuronalen schädigungen
EP0671920A4 (en) AN ANTI-IDIOTYPICAL ANTIBODY AND ITS USE IN THE DIAGNOSIS AND THERAPY OF HIV-RELATED DISEASES.
ATE258065T1 (de) Behandlung von autoimmun-erkrankungen durch orale verabreichung von autoantigenen
BR9306042A (pt) Método para tratar uma doença auto-immune em um mamifero e formas de dosagens farmacêuticas oral e inalável
RU94027680A (ru) Паращитовидный гормон и ралоксифон для увеличения массы кости, фармацевтический состав и способ увеличения костной массы
ES2181676T3 (es) Diagnosis y tratamiento de enfermedades autoinmunitarias.
MA22915A1 (fr) Methodes de traitement de l'osteoporose pour utilisation de faibles doses de phosphonates.
KR890701099A (ko) 기침 및 기관지 협착을 치료하기 위한 5-ht3 수용기 길항물질
PT988043E (pt) Metodo e produto usando notocordio de esturjao para aliviar os sintomas de artrite
DE69829995D1 (de) Multivalente rekombinante antikörper zur behandlung von hrv infektionen
OA08298A (fr) Nouvelles N-(aminométhyl-5 oxazolin-2 yl-2) N'-phénylurées, leur méthode de préparation ainsi que leur application thérapeutique.
DE69729201D1 (de) Sulfonfluoride zur behandlung von der alzheimerischen krankheit